Skip to main content

Advertisement

SpringerLink
Log in

Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC) (OVHIPEC-2)

  • Aso Research Letter
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. https://doi.org/10.3322/caac.21654.

    Article  PubMed  Google Scholar 

  2. Orr B, Edwards RP. Diagnosis and treatment of ovarian cancer. Hematol Oncol Clin North Am. 2018;32(6):943–64. https://doi.org/10.1016/j.hoc.2018.07.010.

    Article  PubMed  Google Scholar 

  3. Mishra M, Singh N, Ghatage P. Past, present, and future of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer. Cureus. 2021;13(6):e15563. https://doi.org/10.7759/cureus.15563.

    Article  PubMed  PubMed Central  Google Scholar 

  4. du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer. 2009;115(6):1234–44. https://doi.org/10.1002/cncr.24149.

    Article  CAS  PubMed  Google Scholar 

  5. van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378(3):230–40. https://doi.org/10.1056/NEJMoa1708618.

    Article  PubMed  Google Scholar 

  6. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34–43. https://doi.org/10.1056/NEJMoa052985.

    Article  CAS  PubMed  Google Scholar 

  7. Tomao F, Bardhi E, Di Pinto A, et al. Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: an updated meta-analysis of randomized clinical trials according to BRCA mutational status. Cancer Treat Rev. 2019;80:101909. https://doi.org/10.1016/j.ctrv.2019.101909.

    Article  CAS  PubMed  Google Scholar 

  8. Koole SN, Schouten PC, Hauke J, et al. Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: results from the phase III OVHIPEC trial. Int J Cancer. 2022;151(8):1394–404. https://doi.org/10.1002/ijc.34124.

    Article  CAS  PubMed  Google Scholar 

  9. Ghirardi V, De Felice F, D’Indinosante M, et al. Hyperthermic intraperitoneal chemotherapy (HIPEC) after primary debulking surgery in advanced epithelial ovarian cancer: is BRCA mutational status making the difference? Cancer Treat Res Commun. 2022;31:100518. https://doi.org/10.1016/j.ctarc.2022.100518.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

    Stephanie N. Gregory MD, Carrie E. Ryan MD, MS & Jonathan M. Hernandez MD

  2. Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Oliver Zivanovic MD

  3. Department of Gynecology, The Netherlands Cancer Institute, Amsterdam, The Netherlands

    S. Lot Aronson MD & Willemien J. van Driel MD

  4. Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands

    Gabe S. Sonke MD

Authors
  1. Stephanie N. Gregory MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carrie E. Ryan MD, MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jonathan M. Hernandez MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gabe S. Sonke MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S. Lot Aronson MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Oliver Zivanovic MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Willemien J. van Driel MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

the OVHIPEC-2 Study Group

Corresponding author

Correspondence to Willemien J. van Driel MD.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 108 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gregory, S.N., Ryan, C.E., Hernandez, J.M. et al. Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC) (OVHIPEC-2). Ann Surg Oncol 30, 1950–1952 (2023). https://doi.org/10.1245/s10434-022-12957-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-022-12957-4

Search

Navigation